BioCentury
ARTICLE | Clinical News

Ceplene: Phase III data

May 17, 2004 7:00 AM UTC

In an international Phase III trial in 320 AML patients in complete remission, Ceplene plus IL-2 increased leukemia-free survival, the primary endpoint, compared to patients receiving no treatment (th...